Science sector lauds UK’s visa scheme, but repeats no-deal Brexit warningBoris Johnson has ordered a new fast-track visa scheme to make it easier for top scientists to work Share XScience sector lauds UK’s visa scheme, but repeats no-deal Brexit warninghttps://pharmaphorum.com/news/science-sector-lauds-uks-visa-scheme-but-repeats-no-deal-brexit-warning/
Bayer boosts cell therapy pipeline with BlueRock acquisitionBayer has announced it is fully acquiring US cell therapy biotech BlueRock Therapeutics, whose cell therapy pipeline includes Share XBayer boosts cell therapy pipeline with BlueRock acquisitionhttps://pharmaphorum.com/news/bayer-boosts-cell-therapy-pipeline-with-bluerock-acquisition/
MSD’s Keytruda plus chemo backed by NICE for lung cancerMerck & Co/MSD’s Keytruda can be provided via the Cancer Drugs Fund for first-line treatment of non-small cell Share XMSD’s Keytruda plus chemo backed by NICE for lung cancerhttps://pharmaphorum.com/news/msds-keytruda-plus-chemo-backed-by-nice-for-lung-cancer/
Pilot study suggests smart devices could help spot early dementiaA preliminary study run by Eli Lilly, Apple and Evidation has suggested that connected smart devices can detect Share XPilot study suggests smart devices could help spot early dementiahttps://pharmaphorum.com/news/pilot-study-suggests-smart-devices-could-help-spot-early-dementia/
Gilead’s Descovy gets FDA panel OK for PrEP, but not for womenGilead’s Descovy got a green light from an FDA advisory committee for HIV pre-exposure prophylaxis (PrEP) yesterday – Share XGilead’s Descovy gets FDA panel OK for PrEP, but not for womenhttps://pharmaphorum.com/news/gileads-descovy-gets-fda-panel-ok-for-prep-but-not-for-women/
Alzheimer’s blood test could boost research after successive trial failuresA blood test could be used to diagnose Alzheimer’s before symptoms arise, providing an alternative to expensive brain Share XAlzheimer’s blood test could boost research after successive trial failureshttps://pharmaphorum.com/news/alzheimers-blood-test-could-boost-research-after-successive-trial-failures/
Google’s DeepMind AI predicts acute kidney injuryArtificial Intelligence can predict acute kidney injury (AKI) 48 hours before it happens, according to new research. Google’s Share XGoogle’s DeepMind AI predicts acute kidney injuryhttps://pharmaphorum.com/news/googles-deepmind-ai-predicts-acute-kidney-injury/
GSK split edges closer as OTC joint venture deal with Pfizer closesThe breakup of GSK has moved a step closer after the companies closed the deal to create the Share XGSK split edges closer as OTC joint venture deal with Pfizer closeshttps://pharmaphorum.com/news/gsk-split-edges-closer-as-otc-joint-venture-deal-with-pfizer-closes/
J&J faces FTC probe on Remicade biosimilar defenceJohnson & Johnson’s antibody blockbuster Remicade has proved highly resistant to biosimilar competition – so much so that Share XJ&J faces FTC probe on Remicade biosimilar defencehttps://pharmaphorum.com/news/jj-faces-ftc-probe-on-remicade-biosimilar-defence/
